MiNK Therapeutics Boosts Cash to $13.4M, Cuts Costs 40%, Advances Phase 2 Trials
MiNK Therapeutics increased cash to $13.4 million and cut operating costs by 40% year-over-year, strengthening its runway for ongoing programs. The company’s iNKT cell platform has advanced into multiple Phase 2 trials for pneumonia/ARDS, solid tumors and autoimmune conditions, with gastric cancer efficacy data due at a major conference.
1. Financial Position Strengthened
MiNK Therapeutics ended Q4 with $13.4 million in cash and reduced operating expenses by nearly 40% year-over-year, extending its capital runway and supporting ongoing clinical programs.
2. Phase 2 Trial Progress
The company’s allogeneic iNKT cell platform has entered randomized Phase 2 trials for hypoxemic pneumonia and ARDS with standard care controls and plans additional studies in IPF, GvHD and solid tumors, showcasing durable immune responses even in steroid-treated patients.
3. Efficacy Data and Partnerships
Efficacy results from the second-line gastric cancer trial will be unveiled at a major conference in H1, and MiNK continues to secure non-dilutive funding and explore potential collaborations for its IL-15 superagonist combination programs.